The invention relates to an oral pharmaceutical composition comprising a probiotic, specifically Lactobacillus acidophilus, combined with an active principle selected from among trimebutine, propinox, lansoprazole, cinitapride, ranitidine and famotidine. The invention also relates to the use thereof for the production of a drug intended for the treatment of functional intestinal disorders, such as irritable bowel syndrome As a first embodiment, the present invention refers to an oral pharmaceutical composition for restoring alterations in intestinal function, which comprises a therapeutically effective amount of an active principle for treating different functional intestinal disorders and a therapeutically effective amount of a probiotic along with pharmaceutically acceptable excipients and optionally a therapeutically effective amount of at least a nutraceutical. An additional embodiment of the present invention refers to the process for preparing an oral pharmaceutical composition that comprises granulating, mixing and compressing a therapeutically effective amount of the active principle for treating functional intestinal disorders and a therapeutically effective amount of a probiotic along with pharmaceutically acceptable excipients. In an additional embodiment, the invention describes the use of a therapeutically effective amount of an active principle for treating different functional intestinal disorders along with a therapeutically effective amount of a probiotic, for the manufacture of a drug for restoring alterations in intestinal functions.La presente invención se refiere a una asociación de Probióticos (PBTs) con diferentes principios activos en monodosis, o con otras asociaciones fijas para restablecer alteraciones de la función intestinal. Por consiguiente, la presente composición resulta ideal en el tratamiento de los distintos trastornos funcionales gastrointestinales y el Síndrome de Intestino Irritable (SII) o Colon irritable (CI). Como una primer
